Interventional cardiologists who participated in a 90-minute course that emphasized radiation safety principals reduced patient radiation dose by 48 percent in diagnostic catheterizations.

Singulex, Inc., the developer and leading provider of Single Molecule Counting (SMC(tm)) technology for clinical diagnostics and scientific discovery, yesterday presented new data at the American Heart Association Epidemiology and Prevention Council Conference highlighting research results using the Company's proprietary ultrasensitive Erenna® Immunoassay System in the detection of cardiac troponin-I (cTnI). The study utilized the Erenna System to measure previously undetected increases in cTnI to predict development of coronary heart disease (CHD) in the general population, independent of a variety of traditional risk factors.

C. R. Bard, Inc. (NYSE: BCR) today announced the enrollment of the first patient into the Lutonix(r) In-Stent Restenosis (ISR) Clinical Trial.  Dr. Carlos Mena, Medical Director, Vascular Medicine at Yale - New Haven Hospital, is the principal investigator of the pivotal multi-center randomized Investigational Device Exemption (IDE) trial which is expected to enroll several hundred patients at 30 sites in the U.S.

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the first enrollments in the company’s LEADLESS Pacemaker Observational Study evaluating the Nanostim™ leadless pacing technology. The Nanostim pacemaker received CE Mark in 2013, and post-approval implants have occurred in the UK, Germany, Italy, Czech Republic, France, Spain, and the Netherlands.

Prominent proteomic and cardiac scientist Jennifer Van Eyk, PhD, has been named the inaugural director of Cedars-Sinai's Advanced Clinical Biosystems Research Institute.

Many American women may not be aware of the warning signs of stroke, according to a study published online March 19 in Stroke. Awareness may be especially low among Hispanic women.

I heard on my car radio that 12.8 million more Americans would receive statins under new cholesterol guidelines. Well, they got the number right.

Almost 13 million Americans between 40 and 75 years old would become eligible for statin therapy under new cholesterol guidelines, according to a study published online March 19 in the New England Journal of Medicine.